Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Enamine Ltd.. (8/1/17). "Press Release: Axxam Enters into a Research Collaboration with Enamine for the Enhancement of the Axxam Screening Collection". Milan & Kiev.

Organisations Organisation Enamine Ltd. (UA)
  Organisation 2 Axxam S.p.A.
Products Product chemical compound library (production)
  Product 2 CNS drug
Index term Index term Axxam–Enamine: chemical compound libraries, 201708– supply expansion addit small molecule compounds for CNS research
Person Person Bossert, Michael (Enamine Ltd 201201 Business Development Director)

Axxam S.p.A. and Enamine Ltd. today announced the start of a Research Collaboration to enhance the Axxam small molecule screening library with the addition of a further set of compounds aimed at early-stage CNS drug discovery, achieving a total library size of ca. 280,000 compounds.

Over the course of the collaboration, Axxam and Enamine scientists will work together to apply a series of literature and proprietary chemoinformatics principles based on generating a highly diverse set of compounds with properties aimed at crossing the blood-brain barrier. Enamine will then provide these compounds, which will significantly augment the existing CNS compound collection at Axxam.

This is the latest phase of a long-standing relationship between the two companies that resulted in the construction of the current AXXDIV2.0 library at Axxam.

Dr. Russell Thomas, Director of Discovery Research at Axxam said “For us, the decision to continue to work with Enamine on this project was very easy. Our current AXXDIV2.0 library, generated entirely by Enamine, has been consistently delivering validated hits in our HTS campaigns that meet our very stringent hit quality criteria across a broad range of target classes. The efforts that we put into generating robust, innovative assays can only be successful when we engage a compound library of the highest standards.

While our existing library continues to perform extremely well, we decided that our next investment in library expansion will be to increase the size of our CNS subset even further. This reflects the fact that we’re seeing a Renaissance in neuroscience drug discovery and we are engaged in an increasing number of neuroscience projects with pharma, biotech and academic research partners around the world.”

Michael Bossert, Head of Strategic Alliances at Enamine said “Axxam and their clients over the years have valued the relevancy and high quality of our design and the resulting in-house made diverse screening compounds we offer. We are pleased to extend our collaboration with Axxam with this latest initiative. Enamine is heavily engaged in the continuous creation of fresh chemistry, large number of novel building blocks and unique screening libraries. Our constantly evolving novel compound offering can satisfy each and every need for most interesting small molecules in our clients’ and partners’ respective research in life science applications at anytime.”

About Axxam S.p.A

Axxam is an innovative Partner Research Organization (iPRO). We are a leading provider of integrated discovery services across Life Sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. We have consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural) or those provided by our clients, compound management, hit identification and hit validation. Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam's business terms are flexible, ranging from fee-for-service to risk-sharing deal structures. For more information, please visit

About Enamine Ltd.

Established in Kiev in 1991, Enamine combines a CRO profile with production and multi-level supply of innovative screening libraries, novel building blocks, fragments, and comprehensive chemistry support in hit discovery and drug discovery solution services, such as organic synthesis, medicinal chemistry, biological screening, ADME-PK testing, as well as fully integrated discovery collaboration. The major catalog assets of the company are a collection of currently 2,300,000 screening compounds and dynamically increasing 250,000 building blocks with 2,000 new building blocks freshly synthesized each month providing a major competitive advantage. Enamine is heavily involved in researching on new synthesis reactions and methodologies, having made over 270 scientific publications in the past 10 years. Enamine serves the pharmaceutical, agrochemical, cosmetic, nutritional and petrochemical industries. For more information, please visit

Record changed: 2019-04-26


Picture [iito] Made Without Love 650x80px

More documents for Enamine Ltd. (UA)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top